Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LENZ Therapeutics (LENZ) Cash & Equivalents: 2022-2023

Historic Cash & Equivalents for Therapeutics (LENZ) over the last 2 years, with Sep 2023 value amounting to $183.0 million.

  • Therapeutics' Cash & Equivalents rose 224.50% to $183.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $183.0 million, marking a year-over-year increase of 224.50%. This contributed to the annual value of $47.7 million for FY2022, which is N/A change from last year.
  • According to the latest figures from Q3 2023, Therapeutics' Cash & Equivalents is $183.0 million, which was up 42.40% from $128.5 million recorded in Q2 2023.
  • Therapeutics' 5-year Cash & Equivalents high stood at $185.1 million for Q1 2022, and its period low was $8.0 million during Q1 2023.
  • Over the past 2 years, Therapeutics' median Cash & Equivalents value was $75.2 million (recorded in 2022), while the average stood at $97.7 million.
  • The largest annual percentage gain for Therapeutics' Cash & Equivalents in the last 5 years was 224.50% (2023), contrasted with its biggest fall of 95.70% (2023).
  • Quarterly analysis of 2 years shows Therapeutics' Cash & Equivalents stood at $47.7 million in 2022, then skyrocketed by 224.50% to $183.0 million in 2023.
  • Its last three reported values are $183.0 million in Q3 2023, $128.5 million for Q2 2023, and $8.0 million during Q1 2023.